MarketPulse

enrollment protocol violations

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

Nektar Therapeutics Hit With Securities Class Action Over Failed Trial Disclosures

Nektar faces securities litigation over alleged misstatements about REZOLVE-AA trial enrollment practices. Stock fell 7.77% after trial failure announcement.
NKTRsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Nektar Therapeutics Faces Securities Fraud Class Action Over Failed Trial Disclosures

Schall Law Firm launches class action against $NKTR for alleged securities fraud tied to REZOLVE-AA trial protocol violations and misstatements between February-December 2025.
NKTRsecurities fraudclass action lawsuit